SCHEDULE: Morgan Stanley Reduces C4 Therapeutics Stake

Morgan Stanley entities have reported a decrease in their beneficial ownership of C4 Therapeutics, Inc. common stock, now holding less than 5% collectively.

Summary

• Morgan Stanley, Morgan Stanley Capital Services LLC, and Morgan Stanley & Co. LLC have collectively reduced their beneficial ownership of C4 Therapeutics, Inc. common stock.
• As of June 30, 2026, the total beneficial ownership reported by these entities is 8,862,002 shares, representing 8.0% of the class of securities.
• Morgan Stanley Capital Services LLC holds 8,718,000 shares (7.9%), and Morgan Stanley & Co. LLC holds 134,047 shares (0.1%).
• Morgan Stanley & Co. LLC has ceased to be the beneficial owner of more than five percent of the class of securities.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a reduction in beneficial ownership by Morgan Stanley entities, indicating a divestment rather than an investment or strategic shift.

Negatives

• Morgan Stanley entities have reduced their stake in C4 Therapeutics, Inc., indicating a potential divestment or shift in investment strategy.
• Morgan Stanley & Co. LLC no longer holds more than 5% of the company's common stock.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it is a disclosure of beneficial ownership.

Management Comments

• As of the date hereof, Morgan Stanley & Co. LLC has ceased to be the beneficial owner of more than five percent of the class of securities.
• In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically report passive ownership stakes. A reduction in stake by a significant financial institution like Morgan Stanley could be interpreted in various ways, from portfolio rebalancing to a signal of reduced conviction, though without further context, it's difficult to ascertain the precise driver.

Stakeholder Impact

• Shareholders may view the reduction in stake by a major financial institution as a potential negative signal, possibly impacting share price in the short term.
• The filing indicates a shift in the ownership structure, with Morgan Stanley entities no longer holding a significant block of shares.

Key Dates

Keywords

C4 Therapeutics, Morgan Stanley, beneficial ownership, Schedule 13G, common stock, securities